Ownership and insider activity for Galectin Therapeutics Inc. (GALT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer.
Price
| Price | $3.68 |
| Market Cap | $242M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-31 | Uihlein Richard E | M-Exempt | 2,550,932 | $10.3M |
| 2026-07-31 | Uihlein Richard E | M-Exempt | 31,825,235 | $95.5M |
| 2026-07-31 | Uihlein Richard E | M-Exempt | ||
| 2026-07-31 | Uihlein Richard E | M-Exempt | ||
| 2026-07-14 | Jamil Khurram | M-Exempt | 16,250 | $49K |
| 2026-07-14 | Jamil Khurram | M-Exempt | 16,250 | $49K |
| 2026-07-14 | Jamil Khurram | S-Sale | 16,250 | $83K |
| 2026-06-26 | Shlevin Harold H. | M-Exempt | 7,732 | $10K |
| 2026-06-29 | Shlevin Harold H. | M-Exempt | 22,268 | $27K |
| 2026-06-29 | Shlevin Harold H. | M-Exempt | 22,268 | $27K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.4M | $3.1M | $8.3M | $47.5M | $27.1M | $39.6M | $18.6M | $25.7M | $15.1M | $17.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $15.8M | $3.8M | $8.8M | $48.2M | $29.5M | $41.8M | $20.6M | $27.7M | $17.3M | $19.4M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $53000 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $1000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $15.8M | $4.2M | $9.0M | $48.5M | $29.6M | $41.8M | $21.3M | $28.2M | $17.5M | $19.5M |
| Accounts Payable | $910000 | $608000 | $297000 | $1.7M | $1.3M | $1.8M | $3.9M | $6.4M | $5.7M | $3.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $21.1M | 0 |
| Total Current Liabilities | $3.8M | $3.0M | $2.1M | $2.8M | $5.4M | $9.0M | $13.0M | $15.7M | $35.4M | $8.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $29.0M | $39.8M | $71.7M | $85.1M | $133.7M |
| Total Liabilities | $3.8M | $3.0M | $2.1M | $2.9M | $5.4M | $39.2M | $53.5M | $88.4M | $120.6M | $145.7M |
| Retained Earnings | -$163.7M | -$181.2M | -$196.2M | -$216.4M | -$240.0M | -$270.7M | -$309.6M | -$354.4M | -$401.6M | -$432.5M |
| Total Equity | $12.0M | $1.2M | $6.9M | $45.6M | $24.2M | $2.6M | -$32.2M | -$60.2M | -$103.1M | -$126.2M |
| Total Debt | 0 | 0 | 0 | $39000 | $44000 | $29.1M | $39.9M | $71.8M | $106.2M | $133.8M |
| Net Debt | -$15.4M | -$3.1M | -$8.3M | -$47.4M | -$27.1M | -$10.6M | $21.3M | $46.1M | $91.1M | $116.0M |
| Working Capital | $12.0M | $851000 | $6.7M | $45.4M | $24.1M | $32.8M | $7.5M | $12.0M | -$18.2M | $11.4M |
Financial Health
| Debt / Equity | -1.06 |
| Current Ratio | 2.42 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -32.60 |
Profitability
| Return on Equity | 24.44% |
| Return on Invested Capital | -174.29% |
| Return on Assets | -157.87% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALT · AURA · DMAC · DRTS · DSGN · ENGN · IMAB
Explore sector: Healthcare · Biotechnology
More sections of GALT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks